NCT05303272 is a Phase 4 clinical trial of Abatacept Prefilled Syringe in Pemphigus Vulgaris, sponsored by Tongji Hospital.

Who is sponsoring NCT05303272?

NCT05303272 is sponsored by Tongji Hospital.

What drugs are being tested in NCT05303272?

Interventions in NCT05303272: Abatacept Prefilled Syringe, Mycophenolate Mofetil 500Mg Tab.

What condition does NCT05303272 study?

NCT05303272 studies Pemphigus Vulgaris.

Is NCT05303272 still recruiting?

NCT05303272 is currently status unknown. Last updated 31 March 2022.

Last reviewed 2022-03-31 · How we verify

NCT05303272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)

Status unknown Phase 4 Last updated 31 March 2022

What this trial tests

Phase 4 trial testing Abatacept Prefilled Syringe in Pemphigus Vulgaris in 60 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
1 September 2022

30 September 2022

Quick facts

Lead sponsor	Tongji Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 February 2021
Primary completion	1 September 2022
Estimated completion	30 September 2022
Sites	1 location across China

Drugs / interventions tested

Abatacept Prefilled Syringe — full drug profile →
Mycophenolate Mofetil 500Mg Tab — full drug profile →

Conditions studied

Pemphigus Vulgaris — all drugs for Pemphigus Vulgaris →

Sponsor

Tongji Hospital

Who can join

Adults 18 to 80, any sex, with Pemphigus Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.Abatacept is a biologic drug that belongs to the class of T-cell co-stimulation modulators and is used for the treatment of autoimmune diseases.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting therapy in pemphigus: Where are we now and where are we going?
Abulikemu K, Hu F, Liang J, Kang X. · · 2023 · cited 15× · PMID 37292301 · DOI 10.1016/j.heliyon.2023.e16679

Verify or expand the search:

Other Tongji Hospital trials

Trials by the same sponsor.

NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05303272 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
Last refreshed: 31 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05303272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing